课题基金 / 基金详情

Physical and mental health multimorbidity across the lifespan (LIfespaN multimorbidity research Collaborative (LINC)).

Physical and mental health multimorbidity across the lifespan (LIfespaN multimorbidity research Collaborative (LINC)).
整个生命周期的身心健康多重病(LIfespaN 多重病研究合作组织(LINC))。
批准号:
MR/W014416/1
负责人:
Marianne Van Den Bree
金额:
$386.63万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2021
资助国家:
英国
项目状态:
未结题
起止时间:
2021 至 --

项目摘要

项目成果

Marianne Van Den Bree的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Multimorbidity (MM) happens when two or more different diseases are present at the same time in an individual. This is common between physical and psychiatric diseases with almost half of people with a psychiatric disease also having a physical disease. As well as about a third of people with a physical disease also having a psychiatric disease. These patients have worse quality of life than those with a single disease, they often struggle to get the best care and are at risk of living less long. A common and serious type of MM is between internalizing diseases (depression and anxiety) and cardiovascular disease (ICV-MM). Still, very little is understood as to how ICV-MM develops and why it happens. We do know however that both internalizing disease and cardiovascular risk (e.g., obesity, cholesterol) tend to begin before adulthood.To really understand how ICV risk develops, we need large studies of people of all ages whose health has been followed over time. Studies of children are crucial because they can tell us about early risks for development of ICV-MM later in life. This is important for developing better plans to prevent at-risk children developing ICV-MM.We know that genes influence risk of both internalizing and cardiovascular disease and that some people are at high genetic risk. We also know that certain conditions that start early in life (neurodevelopmental conditions) such as intellectual disability, autism and ADHD increase risk of developing ICV MM later. Children's environments can also increase this risk, for example, stressful experiences such as poverty and physical or sexual abuse. But how exactly genes, neurodevelopmental conditions and early environmental risks influence the development of ICV-MM over the lifespan is still not understood.Certain groups are known to be at increased risk of ICV-MM, such as people of South Asian heritage and women, but we don't know why this is. Better understanding of how ICV-MM develops in different groups in society will help doctors give patients care that is matched to their specific needs. It will also help doctors, governments and schools prevent ICV-MM in at-risk children in ways that work best for them. To really understand the complexities of ICV-MM development, a team of researchers with a wide range of expertise is needed who together understand physical and psychiatric diseases as well as how genetics, neurodevelopmental conditions and the environments people live in influence them throughout their lives.Our LIfespaN multimorbidity research Collaborative (LINC) combines wide-ranging medical and research expertise in physical and psychiatric diseases. We have brought together five very large studies in which the health of many people has been followed over time. Rich medical data is available, including from medical records. Genetic information is also available for these people. Other important information has also been collected such as on people's living environments, life events and lifestyles. These studies follow the health over time of children, adolescents and adults. We can therefore study how internalizing and cardiovascular disease happen together in adulthood. Importantly we can then also study early risk factors in the children before they develop these conditions. Because our child and adult samples differ in ethnicity and economic situation, we can also study how the development of ICV-MM differs for different groups in society. Finally, because we have genetic data, we can study how genes influence ICV-MM development in people at risk.Our study will help us understand how ICV-MM develops and which circumstances influence this. What we learn will be important for the prevention of ICV-MM in children who are at risk because of genetics, their sex, or ethnic or economic reasons. We will work with patients, doctors and charities to develop specific health advice in order to reduce ICV-MM in at risk groups in the future.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/s41537-024-00445-5
发表时间: 2024-02-21
期刊: SCHIZOPHRENIA
影响因子: --
作者: [Arruda,Ana Luiza, Khandaker,Golam M., Zeggini,Eleftheria]
通讯作者: Zeggini,Eleftheria
Protocol for the Psychosis Immune Mechanism Stratified Medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-dose tocilizumab in patients with psychosis.
精神病免疫机制分层药物(PIMS)试验的方案:一项在精神病患者中单剂量tocilizumab的随机双盲安慰剂对照试验。
DOI: 10.1136/bmjopen-2022-067944
发表时间: 2023-03-24
期刊: BMJ open
影响因子: 2.9
作者: []
通讯作者:
DOI: 10.1101/2021.11.19.21266562
发表时间: 2021-11
期刊: Psychoneuroendocrinology
影响因子: 3.7
作者: [N. Donnelly;B. Perry;H. Jones;G. Khandaker]
通讯作者: N. Donnelly;B. Perry;H. Jones;G. Khandaker
DOI: 10.1016/j.jad.2023.05.033
发表时间: 2023-08-15
期刊: Journal of affective disorders
影响因子: 6.6
作者: [Crick DCP, Sanderson E, Jones H, Goulding N, Borges MC, Clayton G, Carter AR, Halligan S, Lawlor DA, Khandaker GM, Fraser A]
通讯作者: Fraser A
6
    Investigating five large population-based cohort studies to understand for the precursors of multimorbidity risk.
    • 批准号:
      MR/V004905/1
    • 项目类别:
      Research Grant
    • 资助金额:
      $9.45万
    • 财政年份:
      2020
    • 负责人:
      Marianne Van Den Bree
    • 依托单位:
    国内基金
    海外基金
    智障模型小鼠中树突棘可塑性的在体研究
    • 批准号:
      81100839
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      14.0万元
    • 批准年份:
      2011
    • 负责人:
      李威
    • 依托单位: